{"id":189979,"date":"2026-03-23T15:48:18","date_gmt":"2026-03-23T15:48:18","guid":{"rendered":"https:\/\/kamucalisani.net\/?p=189979"},"modified":"2026-03-23T15:48:18","modified_gmt":"2026-03-23T15:48:18","slug":"mucize-ilac-ozempici-birakmak-ciddi-saglik-sorunlarina-yol-aciyor","status":"publish","type":"post","link":"https:\/\/kamucalisani.net\/index.php\/2026\/03\/23\/mucize-ilac-ozempici-birakmak-ciddi-saglik-sorunlarina-yol-aciyor\/","title":{"rendered":"\u201cMucize\u201d ila\u00e7 Ozempic\u2019i b\u0131rakmak ciddi sa\u011fl\u0131k sorunlar\u0131na yol a\u00e7\u0131yor"},"content":{"rendered":"

<\/span> Son y\u0131llarda Ozempic<\/strong> gibi GLP-1 ila\u00e7lar\u0131<\/strong>, kilo kayb\u0131n\u0131n \u00f6tesinde, diyabet tedavisinden kalp hastal\u0131klar\u0131 ve bili\u015fsel bozukluk riskini azaltmaya kadar geni\u015f bir yelpazede fayda sa\u011flad\u0131\u011f\u0131 i\u00e7in \u201cmucizevi<\/strong>\u201d olarak tan\u0131mlan\u0131yor. Hatta ba\u011f\u0131ml\u0131l\u0131k tedavisinde bile umut vadeden etkileri bulunuyor. Ancak ila\u00e7lar\u0131n kullan\u0131m\u0131n\u0131n b\u0131rak\u0131lmas\u0131yla ortaya \u00e7\u0131kan etkiler \u00fczerine yap\u0131lan yeni ara\u015ft\u0131rmalar bu faydalar\u0131n ne kadar \u00e7abuk kaybolabilece\u011fini<\/strong> g\u00f6zler \u00f6n\u00fcne serdi. <\/figure>\n

Washington \u00dcniversitesi T\u0131p Fak\u00fcltesi ara\u015ft\u0131rmac\u0131lar\u0131 taraf\u0131ndan y\u00fcr\u00fct\u00fclen ve BMJ Medicine dergisinde yay\u0131mlanan ara\u015ft\u0131rma, \u00fc\u00e7 y\u0131l boyunca 333.000\u2019den fazla<\/strong> diyabetli yeti\u015fkinin sa\u011fl\u0131k kay\u0131tlar\u0131n\u0131 inceledi. Kat\u0131l\u0131mc\u0131lar\u0131n yakla\u015f\u0131k \u00fc\u00e7te biri, GLP-1 s\u0131n\u0131f\u0131 ilac\u0131 Ozempic<\/strong> (etkin maddesi semaglutide) kullan\u0131yordu. \u00c7al\u0131\u015fma, ilac\u0131n d\u00fczenli kullan\u0131m\u0131n\u0131n uzun vadeli sa\u011fl\u0131k \u00fczerindeki etkilerini ortaya koyarken b\u0131rak\u0131ld\u0131\u011f\u0131nda risklerin h\u0131zla artt\u0131\u011f\u0131n\u0131 g\u00f6sterdi.<\/p>\n

Kullan\u0131m\u0131 b\u0131rakmak ciddi sorunlar yaratabilir<\/b><\/p>\n

Ara\u015ft\u0131rman\u0131n olumlu y\u00f6n\u00fc Ozempic kullanan hastalarda \u00fc\u00e7 y\u0131l boyunca kalp-damar<\/strong> hastal\u0131\u011f\u0131 riskinin y\u00fczde 18 azald\u0131\u011f\u0131n\u0131<\/strong> g\u00f6stermesi oldu. Bu sonu\u00e7, sadece kilo kayb\u0131 sa\u011flamaktan \u00f6te, ilac\u0131n kalp ve metabolik sa\u011fl\u0131\u011fa \u00f6nemli katk\u0131lar sundu\u011funu teyit ediyor.<\/p>\n

<\/span> Ara\u015ft\u0131rman\u0131n olumsuz taraf\u0131<\/strong> ise olduk\u00e7a dikkat \u00e7ekici. \u00c7al\u0131\u015fma, GLP-1 ila\u00e7lar\u0131n\u0131 alt\u0131 ay gibi k\u0131sa bir s\u00fcre i\u00e7in bile b\u0131rakman\u0131n b\u00fcy\u00fck kardiyovask\u00fcler<\/strong> (kalp-damar) olay riskini y\u00fczde 8<\/strong> oran\u0131nda art\u0131rd\u0131\u011f\u0131n\u0131 ortaya koydu. Bu ila\u00e7lar\u0131 kullanmay\u0131 bir veya iki y\u0131l s\u00fcreyle b\u0131rakanlarda ise risk y\u00fczde 22<\/strong> oran\u0131nda y\u00fckselerek<\/strong> ilac\u0131n sa\u011flad\u0131\u011f\u0131 koruma etkisini tamamen ortadan kald\u0131rd\u0131. <\/figure>\n

Ara\u015ft\u0131rman\u0131n yazarlar\u0131ndan, epidemiyolog Ziyad Al-Aly, bu durumu \u201cmetabolik k\u0131r\u0131lma\u201d olarak tan\u0131ml\u0131yor. Al-Aly, verdi\u011fi r\u00f6portajda \u201cKardiyovask\u00fcler koruma olu\u015fturmak y\u0131llar s\u00fcrer ancak bunu ortadan kald\u0131rmak bunun yar\u0131s\u0131 kadar s\u00fcrer\u201d<\/em> dedi.<\/p>\n

B\u0131rakman\u0131n en g\u00f6r\u00fcn\u00fcr etkisi, kilo art\u0131\u015f\u0131 olarak kar\u015f\u0131m\u0131za \u00e7\u0131k\u0131yor. Aktar\u0131lanlara g\u00f6re i\u015ftah yeniden eski seviyesine d\u00f6n\u00fcyor ve kontrol edilmesi zor bir \u015fekilde art\u0131yor. Ayn\u0131 zamanda iltihaplanma, kan bas\u0131nc\u0131 ve kolesterol seviyelerinde de belirgin bir art\u0131\u015f g\u00f6zlemlendi\u011fi belirtiliyor.<\/p>\n

Ara\u015ft\u0131rmac\u0131 Al-Aly\u2019ye g\u00f6re as\u0131l endi\u015fe verici nokta tedaviye ara vermenin hastada “kal\u0131c\u0131 bir iz” b\u0131rakmas\u0131. \u0130la\u00e7 kullan\u0131m\u0131na geri d\u00f6n\u00fclse bile sa\u011flad\u0131\u011f\u0131 koruyucu kalkan bir kez delindi\u011finde eski seviyesine tam olarak ula\u015fam\u0131yor. GLP-1 kullan\u0131c\u0131lar\u0131 aras\u0131nda ilac\u0131 tamamen b\u0131rakma veya d\u00fczensiz kullanma oranlar\u0131n\u0131n y\u00fcksekli\u011fi bu durumu daha da kritik hale getiriyor. \u00c7al\u0131\u015fmaya kat\u0131lanlar\u0131n y\u00fczde 26’s\u0131 ilac\u0131 tamamen b\u0131rak\u0131rken, y\u00fczde 23’\u00fc ise tedaviye yeniden ba\u015flamadan \u00f6nce en az alt\u0131 ayl\u0131k uzun bir ara vermi\u015f.<\/p>\n

\u0130la\u00e7lar\u0131n yan etkileri de g\u00f6z ard\u0131 edilemez boyutta. Ba\u015flang\u0131\u00e7ta hastalar\u0131n yakla\u015f\u0131k %50\u2019sinde bulant\u0131 g\u00f6r\u00fcl\u00fcyor, daha az yayg\u0131n olsa da kusma ve ishal de bildirilen etkiler aras\u0131nda yer al\u0131yor. Ayr\u0131ca, ila\u00e7lar\u0131n maliyeti y\u00fcksek ve y\u00fcksek talep ile \u00fcretim yetersizli\u011fi s\u0131k s\u0131k tedarik s\u0131k\u0131nt\u0131lar\u0131na yol a\u00e7\u0131yor. Ancak bir s\u00fcre \u00f6nce Ozempic ilac\u0131nda bulunan semaglutid etken maddesinin patenti sona erdi<\/strong>. Bu durum \u00e7ok daha ucuz ila\u00e7lar\u0131n piyasaya \u00e7\u0131kmas\u0131na neden olabilir.<\/p>\n\n

Kaynak\u00a0 :\u00a0https:\/\/www.donanimhaber.com\/ozempic-i-birakmak-ciddi-saglik-sorunlarina-yol-aciyor–203532<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Son y\u0131llarda Ozempic gibi GLP-1 ila\u00e7lar\u0131, kilo kayb\u0131n\u0131n \u00f6tesinde, diyabet tedavisinden kalp hastal\u0131klar\u0131 ve bili\u015fsel bozukluk riskini azaltmaya kadar geni\u015f bir yelpazede fayda sa\u011flad\u0131\u011f\u0131 i\u00e7in \u201cmucizevi\u201d olarak tan\u0131mlan\u0131yor. Hatta ba\u011f\u0131ml\u0131l\u0131k …<\/p>\n","protected":false},"author":1,"featured_media":189980,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[12190,6420,4185,2638,641],"class_list":["post-189979","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-teknoloji","tag-birakma","tag-etkiler","tag-ilaci","tag-risk","tag-sure"],"_links":{"self":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/189979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/comments?post=189979"}],"version-history":[{"count":1,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/189979\/revisions"}],"predecessor-version":[{"id":189983,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/189979\/revisions\/189983"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/media\/189980"}],"wp:attachment":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/media?parent=189979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/categories?post=189979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/tags?post=189979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}